✦ LIBER ✦

Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis

✍ Scribed by David Adeboyeku; Sandra Scott; Margaret E. Hodson

Book ID: 119288498
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 100 KB
Volume: 5
Category: Article
ISSN: 1569-1993
DOI: 10.1016/j.jcf.2006.05.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

207 In vitro study of colistin and tobra

207 In vitro study of colistin and tobramycin effectiveness against gram(-) bacteria obtained from cystic fibrosis patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 89 KB

Pharmacokinetic and tolerability profile

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow® rapid and PARI LC Plus® nebulisers in cystic fibrosis patients

✍ Govoni, Mirco; Poli, Gianluigi; Acerbi, Daniela; Santoro, Debora; Cicirello, Hel 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Effect of nebulized colistin sulphate an

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study

✍ E.M. Westerman; P.P.H. Le Brun; D.J. Touw; H.W. Frijlink; H.G.M. Heijerman 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 107 KB

69 Efficacy on lung function and safety

69 Efficacy on lung function and safety of multiple courses of tobramycin 300mg/4mL nebuliser solution (Bramitob) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: results from a 48-week extension phase

✍ H. Mazurek; R. Chiron; G. Varoli; D. Santoro; H. Cicirello; Y. Antipkin 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

WS5.5 A randomised, open label phase 3 s

WS5.5 A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection

✍ M. Goldman; A. Schuster; C. Halliburn; G. Döring 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Multicenter, open-label study of recombi

Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease

✍ H. Karsten Harms; Elias Matouk; Guy Tournier; Horst von der Hardt; Peter H. Well 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB 👁 2 views

Cystic fibrosis is characterized by the accumulation of thick viscous purulent secretions. Recombinant human deoxyribonuclease I (rhDNase) breaks down extracellular DNA, which contributes to the increased viscosity of sputum. A multinational, open-label study was conducted in 974 cystic fibrosis pat